Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Breast Neoplasms 7Lung Neoplasms 6Ovarian Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Testicular Neoplasms 3Stomach Neoplasms 3Sarcoma 3Melanoma 3Fallopian Tube Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Lymphoma, Non-Hodgkin 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Teratoma, Testicular 1

Interventions

pembrolizumab 2entinostat 2sipuleucel-T 1palbociclib 1luprolide acetate gel depot 1ixabepilone 1Taxes 1Pemetrexed 1Paclitaxel 1Leuprolide 1Cisplatin 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Taxes × Genitourinary × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡